On Nov 14, major Wall Street analysts update their ratings for $Sangamo Therapeutics (SGMO.US)$, with price targets ranging from $3 to $10.
Barclays analyst Gena Wang maintains with a buy rating, and maintains the target price at $9.
Wells Fargo analyst Yanan Zhu maintains with a hold rating, and adjusts the target price from $1 to $3.
TD Cowen analyst Ritu Baral maintains with a buy rating.
H.C. Wainwright analyst Patrick Trucchio maintains with a buy rating, and maintains the target price at $10.
Furthermore, according to the comprehensive report, the opinions of $Sangamo Therapeutics (SGMO.US)$'s main analysts recently are as follows:
Following Sangamo's third-quarter report, there's an acknowledgment of the alignment with the FDA for an accelerated approval pathway. The discussion during the Q3 call primarily centered on the advancement of the Fabry program and the ongoing late-stage partnership talks. There is anticipation of favorable data by the third quarter of 2025 and potential FDA approval by 2026, with the expectation of a partnership deal being announced shortly.
The firm considers the establishment of a partnership regarding the Fabry program and the complete results from the pivotal study as crucial catalysts. It is believed that the potential rise in the stock's value will stem from the proof of concept of the company's proprietary ZFP transcription factor neurology programs.
Here are the latest investment ratings and price targets for $Sangamo Therapeutics (SGMO.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
